Empowered Funds LLC Boosts Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Empowered Funds LLC raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 33.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,437 shares of the medical research company’s stock after acquiring an additional 871 shares during the quarter. Empowered Funds LLC’s holdings in IQVIA were worth $814,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. 1832 Asset Management L.P. grew its holdings in shares of IQVIA by 472.3% in the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after purchasing an additional 376,595 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of IQVIA during the second quarter worth $70,610,000. Impax Asset Management Group plc raised its stake in shares of IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after acquiring an additional 264,555 shares in the last quarter. Canada Pension Plan Investment Board boosted its holdings in IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after purchasing an additional 211,653 shares during the period. Finally, D. E. Shaw & Co. Inc. grew its stake in IQVIA by 285.1% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock worth $56,783,000 after purchasing an additional 198,808 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Up 2.1 %

IQVIA stock opened at $201.82 on Friday. The stock has a 50-day simple moving average of $222.67 and a 200-day simple moving average of $227.16. The company has a market capitalization of $36.63 billion, a P/E ratio of 26.49, a PEG ratio of 2.03 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of analyst reports. Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Redburn Atlantic assumed coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 target price on the stock. Evercore ISI lowered their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Truist Financial reduced their price objective on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Finally, TD Cowen lowered their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.